Overview of the molecular and biochemical basis of branched-chain amino acid catabolism

Robert Harris, Mandar Joshi, Nam Ho Jeoung, Mariko Obayashi

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The branched-chain amino acids (BCAAs) are required for protein synthesis and neurotransmitter synthesis. The branched-chain α-ketoacid dehydrogenase complex (BCKDC) is the most important regulatory enzyme in the catabolic pathways of the BCAAs. Activity of the complex is controlled by covalent modification with phosphorylation of its branched-chain α-ketoacid dehydrogenase subunits by a specific kinase [branched-chain kinase (BDK)] causing inactivation and dephosphorylation by a specific phosphatase [branched-chain phosphatase (BDP)] causing activation. Tight control of BCKDC activity is important for conserving as well as disposing of BCAAs. Phosphorylation of the complex occurs when there is a need to conserve BCAAs for protein synthesis; dephosphorylation occurs when BCAAs are present in excess. The relative activities of BDK and BDP set the activity state of BCKDC. BDK activity is regulated by α-ketoisocaproate inhibition and altered level of expression. Less is known about BDP but a novel mitochondrial phosphatase was identified recently that may contribute to the regulation of BCKDC. Reduced capacity to oxidize BCAAs, as in maple syrup urine disease, results in excess BCAAs in the blood and profound neurological dysfunction and brain damage. In contrast, loss of control of BCAA oxidation results in growth impairment and epileptic-like seizures. These findings emphasize the importance of control of BCAA catabolism for normal neurological function. It is proposed that the safe upper limit of dietary BCAA intake could be established with a BCAA tolerance test and clamp protocol.

Original languageEnglish
JournalJournal of Nutrition
Volume135
Issue number6 SUPPL.
StatePublished - Jun 2005

Fingerprint

Branched Chain Amino Acids
branched chain amino acids
amino acid metabolism
3-methyl-2-oxobutanoate dehydrogenase (lipoamide)
3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)
Phosphoric Monoester Hydrolases
phosphotransferases (kinases)
Phosphotransferases
dephosphorylation
phosphorylation
maple syrup urine disease
protein synthesis
Maple Syrup Urine Disease
Phosphorylation
brain damage
acid tolerance
seizures
neurotransmitters
Neurotransmitter Agents
Epilepsy

Keywords

  • Branched-chain α-ketoacid dehydrogenase
  • Branched-chain α-ketoacid dehydrogenase kinase
  • Branched-chain amino acids
  • Branched-chain keto acids
  • Leucine

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science

Cite this

Overview of the molecular and biochemical basis of branched-chain amino acid catabolism. / Harris, Robert; Joshi, Mandar; Jeoung, Nam Ho; Obayashi, Mariko.

In: Journal of Nutrition, Vol. 135, No. 6 SUPPL., 06.2005.

Research output: Contribution to journalArticle

Harris, Robert ; Joshi, Mandar ; Jeoung, Nam Ho ; Obayashi, Mariko. / Overview of the molecular and biochemical basis of branched-chain amino acid catabolism. In: Journal of Nutrition. 2005 ; Vol. 135, No. 6 SUPPL.
@article{a8d77f4cc6484b35a8fec6d84d072a85,
title = "Overview of the molecular and biochemical basis of branched-chain amino acid catabolism",
abstract = "The branched-chain amino acids (BCAAs) are required for protein synthesis and neurotransmitter synthesis. The branched-chain α-ketoacid dehydrogenase complex (BCKDC) is the most important regulatory enzyme in the catabolic pathways of the BCAAs. Activity of the complex is controlled by covalent modification with phosphorylation of its branched-chain α-ketoacid dehydrogenase subunits by a specific kinase [branched-chain kinase (BDK)] causing inactivation and dephosphorylation by a specific phosphatase [branched-chain phosphatase (BDP)] causing activation. Tight control of BCKDC activity is important for conserving as well as disposing of BCAAs. Phosphorylation of the complex occurs when there is a need to conserve BCAAs for protein synthesis; dephosphorylation occurs when BCAAs are present in excess. The relative activities of BDK and BDP set the activity state of BCKDC. BDK activity is regulated by α-ketoisocaproate inhibition and altered level of expression. Less is known about BDP but a novel mitochondrial phosphatase was identified recently that may contribute to the regulation of BCKDC. Reduced capacity to oxidize BCAAs, as in maple syrup urine disease, results in excess BCAAs in the blood and profound neurological dysfunction and brain damage. In contrast, loss of control of BCAA oxidation results in growth impairment and epileptic-like seizures. These findings emphasize the importance of control of BCAA catabolism for normal neurological function. It is proposed that the safe upper limit of dietary BCAA intake could be established with a BCAA tolerance test and clamp protocol.",
keywords = "Branched-chain α-ketoacid dehydrogenase, Branched-chain α-ketoacid dehydrogenase kinase, Branched-chain amino acids, Branched-chain keto acids, Leucine",
author = "Robert Harris and Mandar Joshi and Jeoung, {Nam Ho} and Mariko Obayashi",
year = "2005",
month = "6",
language = "English",
volume = "135",
journal = "Journal of Nutrition",
issn = "0022-3166",
publisher = "American Society for Nutrition",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Overview of the molecular and biochemical basis of branched-chain amino acid catabolism

AU - Harris, Robert

AU - Joshi, Mandar

AU - Jeoung, Nam Ho

AU - Obayashi, Mariko

PY - 2005/6

Y1 - 2005/6

N2 - The branched-chain amino acids (BCAAs) are required for protein synthesis and neurotransmitter synthesis. The branched-chain α-ketoacid dehydrogenase complex (BCKDC) is the most important regulatory enzyme in the catabolic pathways of the BCAAs. Activity of the complex is controlled by covalent modification with phosphorylation of its branched-chain α-ketoacid dehydrogenase subunits by a specific kinase [branched-chain kinase (BDK)] causing inactivation and dephosphorylation by a specific phosphatase [branched-chain phosphatase (BDP)] causing activation. Tight control of BCKDC activity is important for conserving as well as disposing of BCAAs. Phosphorylation of the complex occurs when there is a need to conserve BCAAs for protein synthesis; dephosphorylation occurs when BCAAs are present in excess. The relative activities of BDK and BDP set the activity state of BCKDC. BDK activity is regulated by α-ketoisocaproate inhibition and altered level of expression. Less is known about BDP but a novel mitochondrial phosphatase was identified recently that may contribute to the regulation of BCKDC. Reduced capacity to oxidize BCAAs, as in maple syrup urine disease, results in excess BCAAs in the blood and profound neurological dysfunction and brain damage. In contrast, loss of control of BCAA oxidation results in growth impairment and epileptic-like seizures. These findings emphasize the importance of control of BCAA catabolism for normal neurological function. It is proposed that the safe upper limit of dietary BCAA intake could be established with a BCAA tolerance test and clamp protocol.

AB - The branched-chain amino acids (BCAAs) are required for protein synthesis and neurotransmitter synthesis. The branched-chain α-ketoacid dehydrogenase complex (BCKDC) is the most important regulatory enzyme in the catabolic pathways of the BCAAs. Activity of the complex is controlled by covalent modification with phosphorylation of its branched-chain α-ketoacid dehydrogenase subunits by a specific kinase [branched-chain kinase (BDK)] causing inactivation and dephosphorylation by a specific phosphatase [branched-chain phosphatase (BDP)] causing activation. Tight control of BCKDC activity is important for conserving as well as disposing of BCAAs. Phosphorylation of the complex occurs when there is a need to conserve BCAAs for protein synthesis; dephosphorylation occurs when BCAAs are present in excess. The relative activities of BDK and BDP set the activity state of BCKDC. BDK activity is regulated by α-ketoisocaproate inhibition and altered level of expression. Less is known about BDP but a novel mitochondrial phosphatase was identified recently that may contribute to the regulation of BCKDC. Reduced capacity to oxidize BCAAs, as in maple syrup urine disease, results in excess BCAAs in the blood and profound neurological dysfunction and brain damage. In contrast, loss of control of BCAA oxidation results in growth impairment and epileptic-like seizures. These findings emphasize the importance of control of BCAA catabolism for normal neurological function. It is proposed that the safe upper limit of dietary BCAA intake could be established with a BCAA tolerance test and clamp protocol.

KW - Branched-chain α-ketoacid dehydrogenase

KW - Branched-chain α-ketoacid dehydrogenase kinase

KW - Branched-chain amino acids

KW - Branched-chain keto acids

KW - Leucine

UR - http://www.scopus.com/inward/record.url?scp=20344373417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344373417&partnerID=8YFLogxK

M3 - Article

C2 - 15930464

AN - SCOPUS:20344373417

VL - 135

JO - Journal of Nutrition

JF - Journal of Nutrition

SN - 0022-3166

IS - 6 SUPPL.

ER -